Thursday, February 2, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

New Insights on Cause of Rare Anaphylaxis Following COVID-19 Vaccination

by Global Biodefense Staff
April 7, 2021
New Insights on Cause of Rare Anaphylaxis Following COVID-19 Vaccination

Credit: Noah Sudolcan

On the first day of the UK campaign for COVID-19 vaccination, there were reports of two cases of anaphylaxis–a severe, potentially life-threatening allergic reaction–within minutes of administration of the Pfizer/BioNTech mRNA vaccine. Further cases of suspected anaphylaxis to the Pfizer vaccine were subsequently reported. This was alarming, as anaphylaxis to vaccines is rare; in the order of 1 case per million doses, and therefore likely to injure public confidence.

A new report published in Clinical & Experimental Allergy reveals that an allergy to the ingredient polyethylene glycol (PEG) is a cause of anaphylaxis to the vaccine.

The authors note that very few people are allergic to PEG, and they provide a guide to identifying those who are at risk. “This preliminary report confirms PEG as a cause of anaphylaxis to the Pfizer/BioNTech vaccine, for the first time,” they wrote. “COVID-19 vaccine anaphylaxis and PEG allergy are both rare, so proof of PEG as the cause in one case of vaccine anaphylaxis is important. However, it is important to emphasise that PEG allergy is rare and that COVID-19 vaccines remain safe.”

Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID‐19 vaccine. Clinical & Experimental Allergy, 6 April 2021.

Tags: COVID-19Editor PickEpidemiologymRNASARS-CoV-2Vaccines

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC